Tech Briefs

Bayer’s CEO praises Israeli technology; Gilat to upgrade New Zealand IP’s network; BioCatch completes $10m financing round.

Bloomberg

Bayer’s CEO praises Israeli technology

Bayer, the German-based chemical and pharmaceutical giant, is interested in expanding is cooperation with Israeli tech companies, its CEO Marijn Dekkers has told TheMarker. In Israel on a private visit that included a trip to the top of Masada, the ancient Herodian fortress, a meeting with President Shimon Peres and a stop at Bayer’s Israeli offices, Dekkers said his company would be interested in investing considerable new funding in Israel, although Bayer would not be opening a medical research and development center here in the near future. Nonetheless, Dekkers heaped praise on Israeli entrepreneurship and gave substantial credit to the government for the development of knowledge-based industry here. (Ora Coren)

Gilat to upgrade New Zealand IP’s network

Gilat Satellite Networks announced this week that it will be upgrading the wireless broadband Internet service offered by Wireless Nation, an Internet service provider in New Zealand. The upgrade will provide improvements to the service offered to individual customers, as well as business and government in New Zealand, the Petah Tikva-based satellite firm said, and will use Gilat’s own satellite terminals. Wireless Nation will be focusing on remote areas of the country that currently lack high-speed connectivity, as well as suburban areas. “Gilat’s innovative technology enables us to offer affordable high-speed connectivity that has not been possible with our previous technologies,” said Bill Smale, managing director of Wireless Nation. (Dror Reich)

BioCatch completes $10m financing round

BioCatch, a cyber security firm that has developed technology allowing the authentication of users’ identity based on how they type on a keyboard and other bio-behavioral signs, has completed a $10 million financing round, the company announced Tuesday. Blumberg Capital and the crowd-funding platform OurCrowd led the investment round, which also included prior investors in BioCatch. The company said it would use the cash to expand its research and development activities and to promote sales of its products in the United States and Europe. Following the latest injection of funds, Blumberg Capital and OurCrowd will get seats on the BioCatch board. The company, founded in 2011, has a staff of 20. (Inbal Orpaz)